View upcoming earnings forecasts and in-depth analysis of company forecasts.

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Wall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected financials for Q3 2024 and ...

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York. (AP ...

Pfizer (NYSE:PFE) shares perked up in the premarket on Tuesday as the New York-based pharma giant beat Street forecasts with its Q3 financials and increased its full-year outlook thanks to ...

Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...

Pfizer PFE0.97%increase; green up pointing triangle punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results. The pharmaceutical company raised its ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Paxlovid on its own drove much of Pfizer’s total sales (PDF) haul of $17.7 billion, up 32% year-over-year. Taking out COVID revenues, the company pulled $13.6 billion in sales in a 14% jump ...